中国重型血友病A成人患者低中剂量三级预防治疗突破性出血特点及影响因素
目的研究中国重型血友病A成人患者低中剂量三级预防治疗的突破性出血特点及其影响因素。方法 49例患者（31.53±7.33岁）按照预防剂量分为低剂量组和中剂量组;评估临床出血表型（Pre-AJBR）、72 h FⅧ谷活性、活动能力（FISH评分）,利用＂血友管家＂APP前瞻性记录出血与治疗情况,中位随访6月。结果低剂量组15例;中剂量组34例;低剂量组和中剂量组关节突破性出血（AJBR）为18.79±13.03次/年和9.28±7.02次/年（P=0.016）,自发性出血比例为75.0%和47.7%,存在靶关节患者比例为80%和44%,靶关节出血占比为59%和41%,中位突破性出血出现时间为预防...
Saved in:
| Published in | 南方医科大学学报 Vol. 37; no. 10; pp. 1391 - 1395 |
|---|---|
| Main Author | |
| Format | Journal Article |
| Language | Chinese |
| Published |
南方医科大学南方医院血液科,广东 广州,510515
2017
|
| Subjects | |
| Online Access | Get full text |
| ISSN | 1673-4254 |
| DOI | 10.3969/j.issn.1673-4254.2017.10.18 |
Cover
| Abstract | 目的研究中国重型血友病A成人患者低中剂量三级预防治疗的突破性出血特点及其影响因素。方法 49例患者（31.53±7.33岁）按照预防剂量分为低剂量组和中剂量组;评估临床出血表型（Pre-AJBR）、72 h FⅧ谷活性、活动能力（FISH评分）,利用＂血友管家＂APP前瞻性记录出血与治疗情况,中位随访6月。结果低剂量组15例;中剂量组34例;低剂量组和中剂量组关节突破性出血（AJBR）为18.79±13.03次/年和9.28±7.02次/年（P=0.016）,自发性出血比例为75.0%和47.7%,存在靶关节患者比例为80%和44%,靶关节出血占比为59%和41%,中位突破性出血出现时间为预防注射后40.08 h和46.08 h（P=0.008）,预防注射后0~12 h突破性出血发生率为4.86%和5.18%,72 h FⅧ谷活性〈1%比例为44.4%和34.8%;AJBR与预防消耗因子量负相关（r=-0.57,P=0.000,n=49）;两组AJBR均与FISH评分负相关,与Pre-AJBR正相关（P〈0.05）。结论低中剂量三级预防治疗尚无法使多数中国重型血友病A成人患者获得阻止关节病变进展的目标;因子剂量虽是预防疗效的最主要影响因素,但通过非因子途径也可能改善疗效。 |
|---|---|
| AbstractList | 目的 研究中国重型血友病A成人患者低中剂量三级预防治疗的突破性出血特点及其影响因素.方法49例患者(31.53± 7.33岁)按照预防剂量分为低剂量组和中剂量组;评估临床出血表型(Pre-AJBR)、72 hFⅧ谷活性、活动能力(FISH评分),利用"血友管家"APP前瞻性记录出血与治疗情况,中位随访6月.结果 低剂量组15例;中剂量组34例;低剂量组和中剂量组关节突破性出血(AJBR)为18.79±13.03次/年和9.28±7.02次/年(P=0.016),自发性出血比例为75.0%和47.7%,存在靶关节患者比例为80%和44%,靶关节出血占比为59%和41%,中位突破性出血出现时间为预防注射后40.08 h和46.08 h(P=0.008),预防注射后0~12 h突破性出血发生率为4.86%和5.18%,72 hFⅧ谷活性<1%比例为44.4%和34.8%;AJBR与预防消耗因子量负相关(r=-0.57,P=0.000,n=49);两组AJBR均与FISH评分负相关,与Pre-AJBR正相关(P<0.05).结论 低中剂量三级预防治疗尚无法使多数中国重型血友病A成人患者获得阻止关节病变进展的目标;因子剂量虽是预防疗效的最主要影响因素,但通过非因子途径也可能改善疗效. 目的研究中国重型血友病A成人患者低中剂量三级预防治疗的突破性出血特点及其影响因素。方法 49例患者（31.53±7.33岁）按照预防剂量分为低剂量组和中剂量组;评估临床出血表型（Pre-AJBR）、72 h FⅧ谷活性、活动能力（FISH评分）,利用＂血友管家＂APP前瞻性记录出血与治疗情况,中位随访6月。结果低剂量组15例;中剂量组34例;低剂量组和中剂量组关节突破性出血（AJBR）为18.79±13.03次/年和9.28±7.02次/年（P=0.016）,自发性出血比例为75.0%和47.7%,存在靶关节患者比例为80%和44%,靶关节出血占比为59%和41%,中位突破性出血出现时间为预防注射后40.08 h和46.08 h（P=0.008）,预防注射后0~12 h突破性出血发生率为4.86%和5.18%,72 h FⅧ谷活性〈1%比例为44.4%和34.8%;AJBR与预防消耗因子量负相关（r=-0.57,P=0.000,n=49）;两组AJBR均与FISH评分负相关,与Pre-AJBR正相关（P〈0.05）。结论低中剂量三级预防治疗尚无法使多数中国重型血友病A成人患者获得阻止关节病变进展的目标;因子剂量虽是预防疗效的最主要影响因素,但通过非因子途径也可能改善疗效。 |
| Abstract_FL | Objective To investigate the characteristics of breakthrough bleeding in adult patients with severe hemophilia A (SHA)receiving low-and intermediate-dose FVIII for tertiary prophylaxis and explore the factors affecting the outcomes of the treatment.Methods Forty-nine patients(mean age 31.53±7.33 years)with SHA receiving tertiary prophylaxis FVIII treatment were divided into low-dose group(n=15)and intermediate-dose group(n=34).The data including clinical bleeding phenotype (Pre-AJBR), 72 h FVIII trough activity, and Functional Independence Score in Hemophilia (FISH) were recorded in all the patients,and Hemophilia Steward APP was used to record the bleeding episode and the treatment data.All the patients were followed up for at least 6 months.Results In the low-dose and intermediate-dose groups,the number of joint bleeding(AJBR) episodes were 18.79 ± 13.03 and 9.28 ± 7.02 per year (P=0.016), and the proportions of spontaneous bleeding were 75.0% and 47.7%,respectively.The proportions of patients with target joint were 80% and 44%,target joint bleeding occurred in 59% and 41%, and cataract bleeding after 0-12 h of prophylactic injection occurred in 4.86% and 5.18% of the patients with a median breakthrough bleeding time of 40.08 h and 46.08 h(P=0.008),respectively.The proportions of patients with 72 h FVIII trough activity<1% were 44.4% and 34.8% in the two groups,respectively.AJBR was negatively correlated with the preventive dose consumed(r=-0.57,P=0.000,n=49)and FISH,but positively correlated with Pre-AJBR in the two groups(P<0.05).Conclusion Tertiary prophylaxis with low-and intermediate-dose FVIII is not sufficient to achieve the goal of preventing progression of joint disease in Chinese adult patients with SHA.Although the prophylactic dose is the most important factor to affect the treatment efficacy,other non-factor approaches may also help to improve the efficacy of the treatment. |
| Author | 邱石球;庄金木;周璇;尹瑞雪;柳竹琴;马菲;李颖嘉;孙竞 |
| AuthorAffiliation | 南方医科大学南方医院血液科,广东广州510515 |
| AuthorAffiliation_xml | – name: 南方医科大学南方医院血液科,广东 广州,510515 |
| Author_FL | QIU Shiqiu ZHUANG Jinmu LIU Zhuqin MA Fei YIN Ruixue LI Yingjia ZHOU Xuan SUN Jing |
| Author_FL_xml | – sequence: 1 fullname: QIU Shiqiu – sequence: 2 fullname: ZHUANG Jinmu – sequence: 3 fullname: ZHOU Xuan – sequence: 4 fullname: YIN Ruixue – sequence: 5 fullname: LIU Zhuqin – sequence: 6 fullname: MA Fei – sequence: 7 fullname: LI Yingjia – sequence: 8 fullname: SUN Jing |
| Author_xml | – sequence: 1 fullname: 邱石球;庄金木;周璇;尹瑞雪;柳竹琴;马菲;李颖嘉;孙竞 |
| BookMark | eNo9kE1LAlEYhe_CIDP_RK1azDT33pl77yxF-gKhjXu5zoeN1FgOke5MCjMxgyADIawWQtAicaET_pv5cP5FI0arA-c8533hbICEXbENALahJGKVqLtl0XIcW4SEYkFGiiwiCVIxTiFLgOS_vQ7SjmMVJQViKilESgLdm375g3nU6vqvncVbw-91wv5tJrh79Fw3aH4sGrfe_GEJtZtRq-dN26E7it5vopdxMP4Jn_vh53U4nASNkd9y437YnoXNmd-79-ff_lPXHwzDyXATrJn81DHSf5oC-f29fPZQyB0fHGUzOUEjkAlMNomCNUo5IlRlnGmablCTqAipuqFhpDOTIEYUWTZkBqlMOC9CpjETcq5ijFNgZ3X2itsmt0uFcuWyascPC3q9XNdrteJyFShJkMXs1orVTip26cKK6fOqdcar9UI8FlElRDD-BTuQioo |
| ContentType | Journal Article |
| Copyright | Copyright © Wanfang Data Co. Ltd. All Rights Reserved. |
| Copyright_xml | – notice: Copyright © Wanfang Data Co. Ltd. All Rights Reserved. |
| DBID | 2RA 92L CQIGP W91 ~WA 2B. 4A8 92I 93N PSX TCJ |
| DOI | 10.3969/j.issn.1673-4254.2017.10.18 |
| DatabaseName | 中文期刊服务平台 中文科技期刊数据库-CALIS站点 维普中文期刊数据库 中文科技期刊数据库-医药卫生 中文科技期刊数据库- 镜像站点 Wanfang Data Journals - Hong Kong WANFANG Data Centre Wanfang Data Journals 万方数据期刊 - 香港版 China Online Journals (COJ) China Online Journals (COJ) |
| DatabaseTitleList | |
| DeliveryMethod | fulltext_linktorsrc |
| DocumentTitleAlternate | Breakthrough bleeding in adult patients with severe hemophilia A receiving low-and intermediate-dose FVIII for tertiary prophylaxis：characteristics and influencing factors |
| DocumentTitle_FL | Breakthrough bleeding in adult patients with severe hemophilia A receiving low- and intermediate-dose FVIII for tertiary prophylaxis:characteristics and influencing factors |
| EndPage | 1395 |
| ExternalDocumentID | dyjydxxb201710018 673690263 |
| GrantInformation_xml | – fundername: 南方医科大学临床重点研究项目 funderid: (LC2016ZD016) |
| GroupedDBID | --- 2B. 2C~ 2RA 92F 92I 92L ACGFS ALMA_UNASSIGNED_HOLDINGS CQIGP CW9 F5P RPM TCJ TGQ U1G U5O W91 ~WA 4A8 93N ABJNI PSX |
| ID | FETCH-LOGICAL-c618-84f653c77a26798a8ccde7f69229dec32d8f6286544e481746aab18c8f1aa9333 |
| ISSN | 1673-4254 |
| IngestDate | Thu May 29 04:08:04 EDT 2025 Wed Feb 14 09:56:53 EST 2024 |
| IsPeerReviewed | false |
| IsScholarly | true |
| Issue | 10 |
| Keywords | 低中剂量 breakthrough bleeding severe hemophilia A 重型血友病A low and Intermediate-dose prophylaxis 突破性出血 预防治疗 |
| Language | Chinese |
| LinkModel | OpenURL |
| MergedId | FETCHMERGED-LOGICAL-c618-84f653c77a26798a8ccde7f69229dec32d8f6286544e481746aab18c8f1aa9333 |
| Notes | severe hemophilia A; low and Intermediate-dose; prophylaxis; breakthrough bleeding 44-1627/R Objective To investigate the characteristics of breakthrough bleeding in adult patients with severe hemophilia A（SHA） receiving low-and intermediate-dose FVIII for tertiary prophylaxis and explore the factors affecting the outcomes of the treatment.Methods Forty-nine patients（mean age 31.53±7.33 years） with SHA receiving tertiary prophylaxis FVIII treatment were divided into low-dose group（n=15） and intermediate-dose group（n=34）.The data including clinical bleeding phenotype（Pre-AJBR）,72 h FVIII trough activity,and Functional Independence Score in Hemophilia（FISH） were recorded in all the patients,and Hemophilia Steward APP was used to record the bleeding episode and the treatment data.All the patients were followed up for at least 6 months.Results In the low-dose and intermediate-dose groups,the number of joint bleeding（AJBR）episodes were 18.79±13.03 and 9.28±7.02 per year（P=0.016）,and the proportions of spontaneous bl |
| PageCount | 5 |
| ParticipantIDs | wanfang_journals_dyjydxxb201710018 chongqing_primary_673690263 |
| PublicationCentury | 2000 |
| PublicationDate | 2017 |
| PublicationDateYYYYMMDD | 2017-01-01 |
| PublicationDate_xml | – year: 2017 text: 2017 |
| PublicationDecade | 2010 |
| PublicationTitle | 南方医科大学学报 |
| PublicationTitleAlternate | Journal of Southern Medical University |
| PublicationTitle_FL | Journal of Southern Medical University |
| PublicationYear | 2017 |
| Publisher | 南方医科大学南方医院血液科,广东 广州,510515 |
| Publisher_xml | – name: 南方医科大学南方医院血液科,广东 广州,510515 |
| SSID | ssib051370560 ssib006562552 ssj0002923145 ssib002263520 ssib001186833 |
| Score | 2.1294165 |
| Snippet | 目的研究中国重型血友病A成人患者低中剂量三级预防治疗的突破性出血特点及其影响因素。方法 49例患者（31.53±7.33岁）按照预防剂量分为低剂量组和中剂量组;评估临床出血表... 目的 研究中国重型血友病A成人患者低中剂量三级预防治疗的突破性出血特点及其影响因素.方法49例患者(31.53± 7.33岁)按照预防剂量分为低剂量组和中剂量组;评估临床出血表... |
| SourceID | wanfang chongqing |
| SourceType | Aggregation Database Publisher |
| StartPage | 1391 |
| SubjectTerms | 低中剂量 突破性出血 重型血友病A 预防治疗 |
| Title | 中国重型血友病A成人患者低中剂量三级预防治疗突破性出血特点及影响因素 |
| URI | http://lib.cqvip.com/qk/91170A/201710/673690263.html https://d.wanfangdata.com.cn/periodical/dyjydxxb201710018 |
| Volume | 37 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVAQN databaseName: PubMed Central issn: 1673-4254 databaseCode: RPM dateStart: 20170101 customDbUrl: isFulltext: true dateEnd: 99991231 titleUrlDefault: https://www.ncbi.nlm.nih.gov/pmc/ omitProxy: true ssIdentifier: ssj0002923145 providerName: National Library of Medicine |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnR1Na9RANNQK4kUUFWtVijon2ZpkZpLJcbLdpQh6qtBbyWeLh60fLbQ91WKptdQKghUKUvVQEDxYemhX-m82m-6_8L1JNk21Si0s4e3L-5yXnXlvdmaiaXdN5kHe69MK1UP1CrO44kNaXwmjwOIxpw6LcaPww0fW8GP2YJSP9vTS0qql6Sl_MJg7dl_JaaIKOIgr7pL9j8gWQgEBMMQXrhBhuJ4oxqTGiCuIHCI1ThyXuAA4BMp7kWFqRLikBgQGLmgAjKgrjE0coOGS1CwiBHF0JUjiBzEmkRTZgEdwdWuIiNoRZcJBslxZPb8FSBANQqSNt6RJBEPAEcQ1UTJc3Uy9hRYAICWksgrQicuUdl2xc5SM9hTW2yjfVSpANQKZPxIBsNA1lM-067yLMtEeBkA5B1eMQ8oACy3JRVVz20C7o0RJllsCLkurBFioVPLus6qawVT6gbVOXKoAaDx6SMLRmaw5RKYAdFeJFGUSQEuhmKHp7CPMeu46kEBYsVHBP1mes8k2p6rf1-k9_CsXKFQRPYwHEKiIFgLNqrIUgtR9IJzqvRIKABuNN6uYbmfba_Px0LJpBbp1Vh4ws1N6uh2DXhr-oJwwSqkUfOXHDdPUsRw1TKOOwUIHLrS0B3EYF4fZSbFmNJx9MhvOzPhIhAeHiTPaWRMn4X6bojPwBRC0nKNCTl2qiSws-XmR03OD2np3jgDTNxNLHvVy88Kwc9qd3Or7_7AZT2eZmGyMP4OcU20BbMReY7yUrY5c1C7kZeaAzPqMS1rP3MRlLWztfk829jtLq8mnlYPP88naSrq-KNuv37WazfbC14P5xdb-WyRaXugsrbV2l9PmVufLq87H7fb2z_TDevrtZbq5057fSpaawJ8u76ULe8nam2T_R_J-NdnYTHc2r2gj9dpIdbiSv2WlEliGqAgWW5wGtu2Z-IesJ4IgjOzYckzTgQ6bmqGI1fZ1xiImDJtZnucbIhCx4XkOpfSq1tuYbETXtAEoTaJQp0HEdY_xgPmcA2xARcMjX5hGn9ZfNNDY0-wwHbWu1NEhRn3a7bzJxvIu9sXYHzG_fhKifu08wtlE6Q2td-r5dHQTSocp_5Z6VH4BCg3dgQ |
| linkProvider | National Library of Medicine |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=%E4%B8%AD%E5%9B%BD%E9%87%8D%E5%9E%8B%E8%A1%80%E5%8F%8B%E7%97%85A%E6%88%90%E4%BA%BA%E6%82%A3%E8%80%85%E4%BD%8E%E4%B8%AD%E5%89%82%E9%87%8F%E4%B8%89%E7%BA%A7%E9%A2%84%E9%98%B2%E6%B2%BB%E7%96%97%E7%AA%81%E7%A0%B4%E6%80%A7%E5%87%BA%E8%A1%80%E7%89%B9%E7%82%B9%E5%8F%8A%E5%BD%B1%E5%93%8D%E5%9B%A0%E7%B4%A0&rft.jtitle=%E5%8D%97%E6%96%B9%E5%8C%BB%E7%A7%91%E5%A4%A7%E5%AD%A6%E5%AD%A6%E6%8A%A5&rft.au=%E9%82%B1%E7%9F%B3%E7%90%83&rft.au=%E5%BA%84%E9%87%91%E6%9C%A8&rft.au=%E5%91%A8%E7%92%87&rft.au=%E5%B0%B9%E7%91%9E%E9%9B%AA&rft.date=2017&rft.pub=%E5%8D%97%E6%96%B9%E5%8C%BB%E7%A7%91%E5%A4%A7%E5%AD%A6%E5%8D%97%E6%96%B9%E5%8C%BB%E9%99%A2%E8%A1%80%E6%B6%B2%E7%A7%91%2C%E5%B9%BF%E4%B8%9C+%E5%B9%BF%E5%B7%9E%2C510515&rft.issn=1673-4254&rft.volume=37&rft.issue=10&rft.spage=1391&rft.epage=1395&rft_id=info:doi/10.3969%2Fj.issn.1673-4254.2017.10.18&rft.externalDocID=dyjydxxb201710018 |
| thumbnail_s | http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=http%3A%2F%2Fimage.cqvip.com%2Fvip1000%2Fqk%2F91170A%2F91170A.jpg http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=http%3A%2F%2Fwww.wanfangdata.com.cn%2Fimages%2FPeriodicalImages%2Fdyjydxxb%2Fdyjydxxb.jpg |